Our newsroom provides you with the latest information about the German Breast Group. This section of the website also includes photographic material and information about our events. In addition, our Annual Scientific Reports, which provide an overview of our research activities, can be downloaded here.
We are glad to inform you that the results of a pooled analysis evaluating fatal events during GBG led breast cancer trials have been published in the Breast Cancer
We are pleased to inform you that the results of the randomised phase II GeparNuevo (GBG 89) study that aimed to investigate the addition of durvalumab, a human monoclonal antibody targeting programmed cell death ligand-1 (PD-L1) to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer (TNBC) has been published in the Annals of Oncology.
The long-term follow-up data of the phase III GeparSepto (GBG 69) study that aimed to compare weekly nab-paclitaxel with weekly sb-paclitaxel followed by epirubicin plus cyclophosphamide (EC) as neoadjuvant treatment in patients with primary breast cancer has been published in the Journal of Clinical Oncology.
Data of several GBG studies conducted together with other collaborative study groups will be presented at the upcoming ASCO 2019, which will take place from May 31 to June 4 in Chicago, IL.
Results of a next-generation sequencing (NGS) analysis conducted in the neoadjuvant GeparSepto study (GBG 69) have been published in the Clinical Cancer Research.
The initial results of AURORA were announced at the ESMO Breast Cancer Congress in Berlin.
Data of several GBG research projects will be presented at the ESMO Breast Cancer 2019, which takes place from 2 to 4 May in Berlin, Germany.
We are pleased to inform you that the results of the E-VITA study that evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER2-positive metastatic breast cancer has been published in the Anticancer Drugs.
A translational research study performed with samples obtained from a cohort of patients with HER2-negative breast cancer enrolled in the neoadjuvant GeparQuinto (GBG 44) trial has been published in the International Journey of Cancer.
ESMO Breast Cancer is an annual congress taking place on 2-4 May 2019 in Berlin, Germany.
We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.
Prof. Dr. Sibylle Loibl, CEO of the GBG Forschungs GmbH and Professor at the Goethe University Frankfurt is featured among these researchers in 2018 for her work in breast cancer research.
We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.
Further results from the prospective PANTHER trial focused on obese breast cancer patients treated with adjuvant tailored dose-dense chemotherapy versus standard treatment has been published in the Annals of Oncology.
Data of several GBG trials and translational research projects will be presented at the upcoming SABCS 2018 Congress, which will take place from 4-8 December in San Antonio, Texas, USA.
We’re delighted to announce that the BIG newsletter BIG Research in Focus, Issue 9 is out and has been published on BIG’s website.
Das GBG Jahrestreffen 2019 wird am 14. & 15. März 2019 in Niederrad Frankfurt am Main stattfinden.
A statistical research study that aimed to develop an empirical model for predicting the magnitude of the treatment effects on survival endpoints based on the treatment effects on pathological complete response (pCR) has been published in the Contemporary Clinical Trials.
The 16th St. Gallen International Breast Cancer Conference 2019 in Vienna is less than seven months away.
A review that summarized the available data on endocrine therapy for premenopausal women with HER2-negative hormone receptor-positive metastatic breast cancer (MBC) has been published in the Oncologist.
GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440